1. Fabbri LM, Celli BR, Agustí A, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med. 2023;11(11):1020-1034. https://doi.org/10.1016/S2213-2600(23)00261-8
2. Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. https://doi.org/10.1038/nrdp.2015.67
3. Mitchell C, Zuraw N, Delaney B, et al. Primary care for people with severe mental illness and comorbid obstructive airways disease: a qualitative study of patient perspectives with integrated stakeholder feedback. BMJ Open. 2022;12(3):e057143. https://doi.org/10.1136/bmjopen-2021-057143
4. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425-448. https://doi.org/10.1146/annurev-clinpsy-032813-153657
5. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131. https://doi.org/10.1001/archpsyc.64.10.1123
6. Meesters PD. New horizons in schizophrenia in older people. Age Ageing. 2023;52(9):afad161. https://doi.org/10.1093/ageing/afad161
7. Hsu JH, Chien IC, Lin CH, Chou YJ, Chou P. Increased risk of chronic obstructive pulmonary disease in patients with schizophrenia: a population-based study. Psychosomatics. 2013;54(4):345-351. https://doi.org/10.1016/j.psym.2012.08.003
8. Hetlevik O, Solheim M, Gjesdal S. Use of GP services by patients with schizophrenia: a national cross-sectional register-based study. BMC Health Serv Res. 2015;15:66. https://doi.org/10.1186/s12913-015-0719-1
9. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324-333. https://doi.org/10.1176/appi.ajp.2012.12050599
10. Launders N, Hayes JF, Price G, Osborn DPJ. Clustering of physical health multimorbidity in people with severe mental illness: an accumulated prevalence analysis of United Kingdom primary care data. PLoS Med. 2022;19(4):e1003976. https://doi.org/10.1371/journal.pmed.1003976
11. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med. 2006;21:1133-1137. https://doi.org/10.1111/j.1525-1497.2006.00563.x
12. Partti K, Vasankari T, Kanervisto M, et al. Lung function and respiratory diseases in people with psychosis: population-based study. Br J Psychiatry. 2015;207(1):37-45. https://doi.org/10.1192/bjp.bp.113.141937
13. Khaykin E, Ford DE, Pronovost PJ, Dixon L, Daumit GL. National estimates of adverse events during nonpsychiatric hospitalizations for persons with schizophrenia. Gen Hosp Psychiatry. 2010;32(4):419-425. https://doi.org/10.1016/j.genhosppsych.2010.04.006
14. Schoepf D, Uppal H, Potluri R, Heun R. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci. 2014;264:3-28. https://doi.org/10.1007/s00406-013-0436-x
15. Burke AJ, Hay K, Chadwick A, Siskind D, Sheridan J. High rates of respiratory symptoms and airway disease in mental health inpatients in a tertiary centre. Intern Med J. 2018;48(4):433-438. https://doi.org/10.1111/imj.13594
16. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2-3):135-157. https://doi.org/10.1016/j.schres.2005.02.010
17. Gurpegui M, Martínez-Ortega JM, Aguilar MC, Diaz FJ, Quintana HM, de Leon J. Smoking initiation and schizophrenia: a replication study in a Spanish sample. Schizophr Res. 2005;76(1):113-118. https://doi.org/10.1016/j.schres.2004.12.007
18. Dickerson F, Schroeder J, Katsafanas E, et al. Cigarette smoking by patients with serious mental illness, 1999-2016: an increasing disparity. Psychiatr Serv. 2018;69(2):147-153. https://doi.org/10.1176/appi.ps.201700118
19. Curtis J, Large M, Myles N, Newall HD, Nielssen O, Shiers D. Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry. 2012;73(4):468-475. https://doi.org/10.4088/JCP.11r07222
20. Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234-258. https://doi.org/10.1016/j.drugalcdep.2018.07.011
21. Tashkin DP, Roth MD. Pulmonary effects of inhaled cannabis smoke. Am J Drug Alcohol Abuse. 2019;45(6):596-609. https://doi.org/10.1080/00952990.2019.1627366
22. Stubbs B, Williams J, Gaughran F, Craig T. How sedentary are people with psychosis? A systematic review and meta-analysis. Schizophr Res. 2016;171(1-3):103-109. https://doi.org/10.1016/j.schres.2016.01.034
23. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521-1537. https://doi.org/10.1183/09031936.00046814
24. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD, 2025 report. GOLD Website. Published 2025. Accessed April 2025. http://www.goldcopd.org.
25. Korman N, Stanton R, Vecchio A, et al. The effect of exercise on global, social, daily living and occupational functioning in people living with schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2023;256:98-111. https://doi.org/10.1016/j.schres.2023.04.012
26. Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019;381(18):1753-1761. https://doi.org/10.1056/NEJMra1808803
27. Reilly S, Olier I, Planner C, et al. Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. BMJ Open. 2015;5(12):e009010. https://doi.org/10.1136/bmjopen-2015-009010
28. Lyons MJ, Bar JL, Kremen WS, et al. Nicotine and familial vulnerability to schizophrenia: a discordant twin study. J Abnorm Psychol. 2002;111(4):687-693. https://doi.org/10.1037//0021-843X.111.4.687
29. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421-427. https://doi.org/10.1038/nature13595
30. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42:441-447. https://doi.org/10.1038/ng.571
31. McEvoy JP, Brown S. Smoking in first-episode patients with schizophrenia. Am J Psychiatry. 1999;156(7):1120a-1121. https://doi.org/10.1176/ajp.156.7.1120a
32. Feigenson KA, Kusnecov AW, Silverstein SM. Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev. 2014;38:72-93. https://doi.org/10.1016/j.neubiorev.2013.11.006
33. Miller BJ, Goldsmith DR. Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions. Neuropsychopharmacology. 2017;42:299-317. https://doi.org/10.1038/npp.2016.211
34. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:1696-1709. https://doi.org/10.1038/mp.2016.3
35. Orlovska-Waast S, Köhler-Forsberg O, Brix SW, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol Psychiatry. 2019;24:869-887. https://doi.org/10.1038/s41380-018-0220-4
36. Welham J, Isohanni M, Jones P, McGrath J. The antecedents of schizophrenia: a review of birth cohort studies. Schizophr Bull. 2009;35(3):603-623. https://doi.org/10.1093/schbul/sbn084
37. Sallis HM, Wootton RE, Davey Smith G, Munafò MR. Proxy gene-by-environment Mendelian randomization study of the association between cigarette smoking during pregnancy and offspring mental health. Int J Epidemiol. 2023;52(5):1350-1359. https://doi.org/10.1093/ije/dyad022
38. Salsberry PJ, Chipps E, Kennedy C. Use of general medical services among Medicaid patients with severe and persistent mental illness. Psychiatr Serv. 2005;56(4):458-462. https://doi.org/10.1176/appi.ps.56.4.458
39. Cradock-O'Leary J, Young AS, Yano EM, Wang M, Lee ML. Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv. 2002;53(7):874-878. https://doi.org/10.1176/appi.ps.53.7.874
40. Haussleiter I, Emons B, Hoffmann K, Juckel G. The somatic care situation of people with mental illness. Health Sci Rep. 2021;4(1):e226. https://doi.org/10.1002/hsr2.226
41. Carswell C, Brown JVE, Lister J, et al. The lived experience of severe mental illness and long-term conditions: a qualitative exploration of service user, carer, and healthcare professional perspectives on self-managing co-existing mental and physical conditions. BMC Psychiatry. 2022;22:479. https://doi.org/10.1186/s12888-022-04117-5
42. Druss BG, Rosenheck RA, Desai MM, Perlin JB. Quality of preventive medical care for patients with mental disorders. Med Care. 2002;40(2):129-136. https://doi.org/10.1097/00005650-200202000-00007
43. Hippisley-Cox J, Parker C, Coupland C, Vinogradova Y. Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart. 2007;93(10):1256-1262. https://doi.org/10.1136/hrt.2006.110171
44. Crawford MJ, Jayakumar S, Lemmey SJ, et al. Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. Br J Psychiatry. 2014;205(6):473-477. https://doi.org/10.1192/bjp.bp.113.142521
45. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literarture. J Clin Psychiatry. 2002;63(10):892-909. https://doi.org/10.4088/JCP.v63n1007
46. Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449-468. https://doi.org/10.2147/PPA.S124658
47. Sanduzzi A, Balbo P, Candoli P, et al. COPD: adherence to therapy. Multidiscip Respir Med. 2014;9:60. https://doi.org/10.1186/2049-6958-9-60
48. Vauterin D, Van Vaerenbergh F, Grymonprez M, Vanoverschelde A, Lahousse L. Medication adherence to inhalation therapy and the risk of COPD exacerbations: a systematic review with meta-analysis. BMJ Open Respir Res. 2024;11(1):e001964. https://doi.org/10.1136/bmjresp-2023-001964
49. Corrigan PW, Mittal D, Reaves CM, et al. Mental health stigma and primary health care decisions. Psychiatry Res. 2014;218(1-2):35-38. https://doi.org/10.1016/j.psychres.2014.04.028
50. Gorczynski P, Patel H, Ganguli R. Adherence to diabetes medication in individuals with schizophrenia: a systematic review of rates and determinants of adherence. Clin Schizophr Relat Psychoses. 2017;10(4):191-200. https://pubmed.ncbi.nlm.nih.gov/24496045/
51. Huetsch JC, Uman JE, Udris EM, Au DH. Predictors of adherence to inhaled medications among Veterans with COPD. J Gen Intern Med. 2012;27:1506-1512. https://doi.org/10.1007/s11606-012-2130-5
52. Free C, Phillips G, Watson L, et al. The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis. PLoS Med. 2013;10(1):e1001363. https://doi.org/10.1371/journal.pmed.1001363
53. Simon E, Edwards AM, Sajatovic M, Jain N, Montoya JL, Levin JB. Systematic literature review of text messaging interventions to promote medication adherence among people with serious mental illness. Psychiatr Serv. 2022;73(10):1153-1164. https://doi.org/10.1176/appi.ps.202100634
54. Aung H, Tan R, Flynn C, et al. Digital remote maintenance inhaler adherence interventions in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(174):240136. https://doi.org/10.1183/16000617.0136-2024
55. Prah P, Petersen I, Nazareth I, Walters K, Osborn D. National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. Pharmacoepidemiol Drug Saf. 2012;21(2):161-169. https://doi.org/10.1002/pds.2213
56. Richards-Belle A, Launders N, Hardoon S, et al. Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000-2019: 20-year investigation of who receives treatment, with which agents and at what doses. Br J Psychiatry. 2025;226(5):269-277. https://doi.org/10.1192/bjp.2024.186
57. Fee R, Webb N, Dick L, et al. Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: claims-linked chart study. J Manag Care Spec Pharm. 2024;30(7):698-709. https://doi.org/10.18553/jmcp.2024.23319
58. Taylor DM, Barnes TRE, Young AH. Schizophrenia and related psychoses. In: Taylor DM, Barnes TRE, Young AH, eds. The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons, Ltd.; 2021:1-278. https://doi.org/10.1002/9781119870203.mpg001
59. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656-663. https://doi.org/10.1093/schbul/sbu164
60. Wang MT, Tsai CL, Lin CW, Yeh CB, Wang YH, Lin HL. Association between antipsychotic agents and risk of acute respiratory failure in patients with chronic obstructive pulmonary disease. JAMA Psychiatry. 2017;74(3):252-260. https://doi.org/10.1001/jamapsychiatry.2016.3793
61. Perez-Vilar S, Mosholder AD, Smith ER, et al. Antipsychotics and risk of acute respiratory failure in U.S. Medicare beneficiaries with chronic obstructive pulmonary disease. J Gen Intern Med. 2024;40:587-594. https://doi.org/10.1007/s11606-024-09208-5
62. Kuo CJ, Yang SY, Liao YT, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull. 2013;39(3):648-657. https://doi.org/10.1093/schbul/sbr202
63. Bonkat N, Fellendorf FT, Dalkner N, Reininghaus EZ. Severe mental disorders and vaccinations - a systematic review. World J Biol Psychiatry. 2022;23(7):501-516. https://doi.org/10.1080/15622975.2021.2013095
64. Maguire PA, Reay RE, Looi JCL. Nothing to sneeze at - uptake of protective measures against an influenza pandemic by people with schizophrenia: willingness and perceived barriers. Australas Psychiatry. 2018;27(2):171-178. https://doi.org/10.1177/1039856218815748
65. Miles LW, Williams N, Luthy KE, Eden L. Adult vaccination rates in the mentally ill population: an outpatient improvement project. J Am Psychiatr Nurses Assoc. 2019;26(2):172-180. https://doi.org/10.1177/1078390319831763
66. Le Glaz A, Lemey C, Berrouiguet S, Walter M, Lemogne C, Flahault C. Physicians' and medical students' beliefs and attitudes toward psychotic disorders: a systematic review. J Psychosom Res. 2022;163:111054. https://doi.org/10.1016/j.jpsychores.2022.111054
67. Sartorius N. Stigma and mental health. Lancet. 2007;370(9590):810-811. https://doi.org/10.1016/S0140-6736(07)61245-8
68. Oud MJT, Schuling J, Slooff CJ, Groenier KH, Dekker JH, Meyboom-de Jong B. Care for patients with severe mental illness: the general practitioner's role perspective. BMC Prim Care. 2009;10:29. https://doi.org/10.1186/1471-2296-10-29
69. De Hert M, van Winkel R, Silic A, Van Eyck D, Peuskens J. Physical health management in psychiatric settings. Eur Psychiatry. 2010;25(S2):S22-S28. https://doi.org/10.1016/S0924-9338(10)71702-8
70. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6(8):675-712. https://doi.org/10.1016/s2215-0366(19)30132-4
71. Druss BG, Rohrbaugh RM, Levinson CM, Rosenheck RA. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry. 2001;58(9):861-868. https://doi.org/10.1001/archpsyc.58.9.861
72. Bressington D, Mui J, Wells H, et al. Refocusing on physical health: community psychiatric nurses' perceptions of using enhanced health checks for people with severe mental illness. Int J Ment Health Nurs. 2016;25(3):214-224. https://doi.org/10.1111/inm.12195
73. Viron M, Baggett T, Hill M, Freudenreich O. Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. Am J Med. 2012;125(3):223-230. https://doi.org/10.1016/j.amjmed.2011.05.002
74. Jones R, Major B, Fear C. Schizophrenia in a primary care setting. Curr Psychiatry Rep. 2015;17:84. https://doi.org/10.1007/s11920-015-0620-y
75. Jacobs R, Aylott L, Dare C, et al. The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study. Health Soc Care Deliv Res. 2020;8(25). https://doi.org/10.3310/hsdr08250
76. Osborn DPJ, King MB, Nazareth I. Participation in screening for cardiovascular risk by people with schizophrenia or similar mental illnesses: cross sectional study in general practice. BMJ. 2003;326:1122. https://doi.org/10.1136/bmj.326.7399.1122
77. Bansal N, Karlsen S, Sashidharan SP, Cohen R, Chew-Graham CA, Malpass A. Understanding ethnic inequalities in mental healthcare in the UK: a meta-ethnography. PLoS Med. 2022;19(12):e1004139. https://iris.who.int/bitstream/handle/10665/275718/9789241550383-eng.pdf
78. World Health Organization (WHO). Management of physical health conditions in adults with severe mental disorders: WHO guidelines. WHO website. Published 2018. Accessed April 2025. https://www.who.int/publications/i/item/978-92-4-155038-3
79. Daumit GL, Dalcin AT, Dickerson FB, et al. Effect of a comprehensive cardiovascular risk reduction intervention in persons with serious mental illness: a randomized clinical trial. JAMA Netw Open. 2020;3(6):e207247. https://doi.org/10.1001/jamanetworkopen.2020.7247
80. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-2520. https://doi.org/10.1016/S0140-6736(16)30272-0
81. Brody AL, Zorick T, Hubert R, et al. Combination extended smoking cessation treatment plus home visits for smokers with schizophrenia: a randomized controlled trial. Nicotine Tob Res. 2017;19(1):68-76. https://doi.org/10.1093/ntr/ntw190
82. Duffy SA, Kilbourne AM, Austin KL, et al. Risk of smoking and receipt of cessation services among veterans with mental disorders. Psychiatr Serv. 2012;63(4):325-332. https://doi.org/10.1176/appi.ps.201100097
83. Szatkowski L, McNeill A. The delivery of smoking cessation interventions to primary care patients with mental health problems. Addiction. 2013;108(8):1487-1494. https://doi.org/10.1111/add.12163
84. Brown CH, Medoff D, Dickerson FB, et al. Factors influencing implementation of smoking cessation treatment within community mental health centers. J Dual Diagn. 2015;11(2):145-150. https://doi.org/10.1080/15504263.2015.1025025
85. Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018;54:124-144. https://doi.org/10.1016/j.eurpsy.2018.07.004
86. Kimhy D, Ospina LH, Wall M, et al. Telehealth-based vs in-person aerobic exercise in individuals with schizophrenia: comparative analysis of feasibility, safety, and efficacy. JMIR Ment Health. 2025;12:e68251. https://doi.org/10.2196/68251
87. Barnes TRE, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2019;34(1):3-78. https://doi.org/10.1177/0269881119889296